SPATA31 subfamily D member 5, pseudogeneGenealiases: FAM75D5 · FAM75D5P
Q-omics provides the consensus-scored SPATA31D5P profile across patient tissues and cancer cell-line models. SPATA31D5P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPATA31D5P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, SPATA31D5P mutation status shows 6,226 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where SPATA31D5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31D5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31D5P survival associations across molecular data types. SPATA31D5P RNA expression shows survival associations in the most cancer types (15), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31D5P RNA expression–survival associations across cancer types. High SPATA31D5P expression shows unfavorable associations in KIRC, THCA, UCS, LUSC, LUAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPATA31D5P RNA expression.
This table summarizes SPATA31D5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31D5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31D5P shows lower tumor expression in BRCA and higher tumor expression in KIRC and ESCA. The KIRC box plot shows higher SPATA31D5P RNA expression in tumor versus normal tissue (log2 FC = +0.003, t-test p = .007).
This table shows molecular features associated with SPATA31D5P in patient tissues and cancer cell lines. In patient samples, SPATA31D5P shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA31D5P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
